Peptide Comparison
Enclomiphene vs hCG
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Depends on goal
The decisive difference is where each one acts. Enclomiphene blocks estrogen receptors at the hypothalamus, which lifts negative feedback and raises LH and FSH, so it requires a pituitary that still responds. hCG is an LH-receptor agonist that stimulates Leydig cells directly, so it works whether or not the pituitary does. Enclomiphene is oral and completed Phase 3 without ever being approved as a standalone product. hCG is FDA-approved and injected. Both preserve fertility markers that exogenous testosterone suppresses. Consult a qualified clinician before any human use.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
The actual difference
Enclomiphene is a selective estrogen receptor modulator rather than a peptide, taken orally, with a half-life near 10 hours. hCG is a placental glycoprotein hormone given IM or SC, with a half-life of roughly 24 hours recombinant and 33 hours urine-derived. The two mechanisms sit at opposite ends of the same axis: one acts above the pituitary, the other below it.
Which one to pick
Pick Enclomiphene if
- The hypothalamic-pituitary axis is intact and the goal is to raise endogenous production through it
- An oral route is required
- Wiehle 2016 is the relevant reference: enclomiphene raised total testosterone, LH and FSH while maintaining sperm concentration in the normal range, where topical testosterone raised testosterone and suppressed sperm counts
Pick hCG if
- Pituitary output is absent or unreliable, since hCG acts downstream of it
- An approved product with a published label is required
- The context is testicular preservation during exogenous testosterone, where Hsieh 2013 reported low-dose hCG maintaining semen parameters
Avoid both if
- There is suspected or confirmed prostate cancer or other androgen-dependent neoplasia
- Testosterone has been measured on only one morning sample, since a single low reading is not a diagnosis
- The patient is female and pregnant or planning pregnancy, where hCG carries documented ovarian hyperstimulation and thromboembolism risk
Common confusions
- 'Enclomiphene is FDA-approved'. It is not. It completed Phase 3 for secondary hypogonadism and was never approved as a standalone product, so every supply route is off-label, compounded or research-labeled.
- 'hCG and enclomiphene do the same thing'. They raise testosterone from different points on the axis. Enclomiphene needs a responsive pituitary. hCG replaces the pituitary's signal. Where the hypogonadism is pituitary in origin, that difference decides whether a compound can work at all.
- 'Clomiphene and enclomiphene are interchangeable'. Clomiphene citrate is a mixture of two isomers. Enclomiphene is the trans isomer isolated on its own. Zuclomiphene, the other isomer, has a far longer half-life and estrogenic activity, which is the stated reason for separating them.
Side-by-side
| Enclomiphene | hCG | |
|---|---|---|
| Class | SERM (non-peptide) | Placental glycoprotein hormone (FDA-approved); LH-receptor agonist |
| Drug class | Sexual-Health | Sexual-Health |
| Mechanism | Estrogen receptor antagonist at hypothalamus; raises LH/FSH and endogenous testosterone | LH-receptor agonist with minor FSH-like activity; in males stimulates testicular Leydig cells to produce endogenous testosterone; in females maintains corpus luteum progesterone production and triggers ovulation |
| Route | Oral | IM / SC |
| Half-life | ~10 hrs | ~33 hrs (urine-derived); ~24 hrs (recombinant) |
| Dosage (research) | 12.5-25 mg oral daily | Female ovulation trigger: 5,000-10,000 USP units IM single dose 1 day after final gonadotropin (FDA Pregnyl/Novarel label). Male off-label: 250 IU SC 2x weekly TRT adjunct (Bhasin Endocrine Society 2018 starting dose, may go higher per response); 1,000 IU IM 2x weekly HPG restart (Crisler protocol starting dose) |
| Evidence tier | Phase 3 (not approved standalone) | FDA-Approved |
| Research depth | 190 indexed | 274 indexed |
| Availability | Research / Off-Label | Prescription |
| Reported risks | Vision changes; mood changes; headache | Ovarian hyperstimulation syndrome (OHSS); thromboembolism; gynecomastia (males at high dose); arterial-thrombosis case reports; contraindicated in suspected/confirmed prostate or other androgen-dependent neoplasia; precocious puberty risk in pediatric use |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Enclomiphene or hCG?
The decisive difference is where each one acts. Enclomiphene blocks estrogen receptors at the hypothalamus, which lifts negative feedback and raises LH and FSH, so it requires a pituitary that still responds. hCG is an LH-receptor agonist that stimulates Leydig cells directly, so it works whether or not the pituitary does. Enclomiphene is oral and completed Phase 3 without ever being approved as a standalone product. hCG is FDA-approved and injected. Both preserve fertility markers that exogenous testosterone suppresses. Consult a qualified clinician before any human use.
What is the difference between Enclomiphene and hCG?
Enclomiphene is classed as SERM (non-peptide); hCG is classed as Placental glycoprotein hormone (FDA-approved); LH-receptor agonist. Reported mechanism: Enclomiphene, Estrogen receptor antagonist at hypothalamus; raises LH/FSH and endogenous testosterone; hCG, LH-receptor agonist with minor FSH-like activity; in males stimulates testicular Leydig cells to produce endogenous testosterone; in females maintains corpus luteum progesterone production and triggers ovulation. Reported half-life: Enclomiphene, ~10 hrs; hCG, ~33 hrs (urine-derived); ~24 hrs (recombinant). Routes in published studies: Enclomiphene, Oral; hCG, IM / SC.
Which has stronger evidence, Enclomiphene or hCG?
hCG has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Enclomiphene is graded Phase 3 (not approved standalone), with 5 cited sources on its reference page and 190 indexed studies. hCG is graded FDA-Approved, with 23 cited sources on its reference page and 274 indexed studies.
Which is more accessible, Enclomiphene or hCG?
hCG is FDA-approved and Enclomiphene is not. Catalog status: Enclomiphene, Research / Off-Label; hCG, Prescription.
Are Enclomiphene and hCG ever combined?
Enclomiphene and hCG appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…